Article
Medicine, Research & Experimental
Jiajin Wu, Chenkui Miao, Yuhao Wang, Songbo Wang, Zhongyuan Wang, Yiyang Liu, Xiaoyi Wang, Zengjun Wang
Summary: This study demonstrates that SPTBN1 is significantly down-regulated in ccRCC and its knockdown promotes ccRCC progression. Overexpression of SPTBN1 reverses this effect. Further investigations reveal that SPTBN1 mediates ccRCC development through the GPT2-dependent glycolysis pathway and regulates the mRNA stability of GPT2 as an RNA-binding protein.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Qianwei Xing, Tengyue Zeng, Shouyong Liu, Hong Cheng, Limin Ma, Yi Wang
Summary: A novel signature based on 10 prognostic GRGs was successfully established and externally and internally validated for predicting OS of ccRCC, assisting clinicians in better predicting patients' survival.
Article
Medicine, General & Internal
Tinghao Li, Hang Tong, Junlong Zhu, Zijia Qin, Siwen Yin, Yan Sun, Xudong Liu, Weiyang He
Summary: A novel three-glycolysis-related lncRNA signature was identified as a promising model for accurate prognoses of patients with ccRCC. Silencing LINC00342 from the signature could partly inhibit the glycolysis level and migration of ccRCC cells.
FRONTIERS IN MEDICINE
(2022)
Article
Genetics & Heredity
Honghao Cao, Hang Tong, Junlong Zhu, Chenchen Xie, Zijia Qin, Tinghao Li, Xudong Liu, Weiyang He
Summary: This study demonstrated the clinical significance of a glycolysis-based lncRNAs signature in predicting the prognosis of RCC patients, showing its reliability and independence compared to traditional clinical parameters. The findings suggest that this signature could potentially serve as a target for future treatment approaches.
FRONTIERS IN GENETICS
(2021)
Article
Cell Biology
Wenqing Lu, Xiaofang Che, Xiujuan Qu, Chunlei Zheng, Xianghong Yang, Bowen Bao, Zhi Li, Duo Wang, Yue Jin, Yizhe Wang, Jiawen Xiao, Jianfei Qi, Yunpeng Liu
Summary: This study comprehensively analyzed the role of succinylation regulators in ccRCC and suggested their specific and critical impact on tumor prognosis. By clustering patients based on the expression patterns of regulators, distinct clusters with different survival outcomes and clinicopathological features were identified, indicating their potential mechanisms in promoting malignant progression. The study provided new insights into the understanding of succinylation modification and its clinical implications in ccRCC treatments.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Olga Katzendorn, Inga Peters, Natalia Dubrowinskaja, Hossein Tezval, Pouriya Faraj Tabrizi, Christoph A. von Klot, Joerg Hennenlotter, Marcel Lafos, Markus A. Kuczyk, Juergen Serth
Summary: Our study revealed a significant association between TACSTD2 methylation and disease progression and clinical course of RCC, indicating a potential role of this gene in the development of RCC.
Article
Genetics & Heredity
Wuping Yang, Lei Li, Kenan Zhang, Kaifang Ma, Yanqing Gong, Jingcheng Zhou, Kan Gong
Summary: The study identified the clinical roles of CLDN10 in clear cell renal cell carcinoma (ccRCC), showing that reduced expression of CLDN10 is associated with metastasis and poor prognosis, while elevated expression is independently correlated with longer overall survival and disease-free survival. Furthermore, CLDN10 expression is negatively associated with DNA methylation levels and immune cell infiltration.
Article
Biochemistry & Molecular Biology
Kun He, Mengyi Xie, Weifeng Hong, Yonghe Li, Yaolin Yin, Xiaojin Gao, Yi He, Yu Chen, Chuan You, Jingdong Li
Summary: Centromere protein L (CENPL) is overexpressed in hepatocellular carcinoma (HCC) and is associated with poor patient prognosis. Upregulation of CENPL promotes tumor proliferation and glycolysis in HCC cells by activating the MEK1/2-ERK1/2 signaling pathway.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2024)
Article
Cell Biology
Xuejie Yang, Cheng Mei, Hui Nie, Jianhua Zhou, Chunlin Ou, Xiaoyun He
Summary: An integrated study using multiple databases was conducted to investigate the diagnostic and prognostic biomarkers of kidney renal clear cell carcinoma (KIRC). The GATA family members were found to have potential as prognostic biomarkers and therapeutic targets for KIRC. The expression profiles of GATA2/3/6 were significantly lower in KIRC samples compared to normal samples, and their levels were closely related to KIRC's pathological grades, clinical stages, and lymph node metastases.
Article
Cell Biology
Chenmin Sun, Min Liu, Wenyi Zhang, Shuyan Wang, Gang Qian, Mi Wang, Guangming Zhang
Summary: The study identified the association between ENO2 expression and clinicopathological parameters in papillary renal cell carcinoma (pRCC), with ENO2 overexpression correlated with poorer prognosis and glycolysis. ENO2-targeted therapy may have therapeutic potential based on the findings.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Oncology
Zhengtong Lv, Lin Qi, Xiheng Hu, Miao Mo, Huichuan Jiang, Yuan Li
Summary: Accumulated evidences suggest significant alterations in aerobic glycolysis in ccRCC. A seven-mRNA signature was identified to predict survival outcomes and serve as an independent prognostic indicator for ccRCC patients. The model can also predict patients' responses to TKI therapy and immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jun Li, Shiqiang Zhang, Dingzhun Liao, Qian Zhang, Chujie Chen, Xiangwei Yang, Donggen Jiang, Jun Pang
Summary: PFKFB3 is significantly up-regulated in RCC specimens and cell lines, correlating with later TNM stages and serving as a robust prognostic biomarker for ccRCC cases. PFKFB3 knockdown suppresses cell glycolysis, proliferation, and cell-cycle G1/S conversion in RCC cells. These results suggest PFKFB3 is a key molecular player in RCC progression and may serve as a potential therapeutic target against RCC.
Article
Pharmacology & Pharmacy
Ganggang Wang, Zheng Wang, Haiquan Lu, Zhiqun Zhao, Liqiang Guo, Feng Kong, Aizhen Wang, Shengtian Zhao
Summary: FRAS1/FREM family members showed significantly decreased expression in KIRC tissues, which was associated with advanced clinicopathological parameters and poor prognosis. They could potentially exert anti-tumor effects by regulating immune infiltrating cells and participating in oncogenic signaling pathways and metabolic pathways. High expression of FRAS1 and FREM2 could serve as reliable predictors of targeted therapeutic drug response.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Fan Zhang, Junyu Lin, Dechao Feng, Jiayu Liang, Yiping Lu, Zhihong Liu, Xianding Wang
Summary: This study explored the correlation between cuprotosis and clear cell renal cell carcinoma (ccRCC) and developed a cuprotosis-related signature to predict the prognosis of patients with ccRCC. The signature risk score was significantly associated with tumor stage, histological grade, and immune cell infiltrates in ccRCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Zhiyu Qiu, Chenwei Wang, Pinzhu Huang, Yichuan Yuan, Yunxing Shi, Zhu Lin, Zhenkun Huang, Dinglan Zuo, Jiliang Qiu, Wei He, Jingxian Shen, Yi Niu, Yunfei Yuan, Binkui Li
Summary: RFX6 acts as a key regulator in the development of HCC by promoting aerobic glycolysis and accelerating the progression of HCC. Elevated expression of RFX6 is associated with poor prognosis in HCC patients.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)